Co-Diagnostics (DE:C970)
NASDAQ:C970
Want to see DE:C970 full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
―Last Year’s EPS
-0.2Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Neutral
The call communicated meaningful operational and regulatory progress across multiple strategic fronts — completed upper respiratory enrollment (>1,400 patients), India manufacturing license and expanded TAM (~$13B), TB clinical start timing, land allocation in Saudi Arabia, and manufacturing automation plans (~4x efficiency). However, the company still reports very limited absolute revenue, a negative gross margin, widening net loss and adjusted EBITDA losses, and a substantial cash decline to $8.2M with an anticipated need for additional capital. Program-level uncertainties (COVID prevalence affecting submission scope), unfinished manufacturing rollouts and no assurance on strategic transactions temper the positive operational milestones. Overall, operational momentum is clear, but financial constraints and execution risks balance the outlook.Company Guidance
Revenue Growth Year-over-Year
Total revenue for Q1 2026 was $146,000, up from $50,000 in Q1 2025, an increase of approximately 192% YoY, demonstrating early commercial traction despite low absolute dollar levels.
Upper Respiratory Clinical Enrollment Completed (>1,400 Patients)
Clinical study enrollment for the upper respiratory multiplex test exceeded 1,400 patients. Management believes the data supports an initial 510(k) submission focused on Flu A, Flu B and RSV and is preparing to file for CLIA-waived point-of-care clearance, targeted for Q3 2026 (subject to validations).
India (CoSara) Regulatory and Manufacturing Progress
CoSara has a nationwide commercial presence, has served hundreds of laboratory customers, holds 15 clinical PCR test clearances from CDSCO, received a CDSCO license to manufacture the PCR Pro instrument, and has expanded distribution across South Asia increasing the total addressable market to about $13 billion.
TB Program Advancement and Alignment with WHO Guidance
Clinical performance studies for the MTB (TB) test are scheduled to begin before month-end; management expects potential commercialization in India as early as end of Q3 2026. The test design aligns with recent WHO recommendations for near point-of-care molecular TB testing and tongue swab samples.
Saudi Arabia (CoMira) Expansion Milestone
CoMira secured industrial land allocation in Sudair Industrial City, progressed facility lease and site development, and completed initial required funding contributions, positioning the JV for localized manufacturing and potential procurement advantages in the MENA region.
Manufacturing Capacity and Automation Improvements
Utah facility has produced hundreds of thousands of test cups for studies and R&D and is developing an automated test cup manufacturing line expected to improve efficiency by ~4x in time and overhead, reducing manual steps and potential errors.
Platform and Pipeline Diversification
Continued advancement of non-TB programs (HPV in preclinical/qualification, expanding Vector placements), cloud-connected architecture with ML/algorithmic capabilities, and ongoing automation in consumable production, supporting broader use cases and scalability.
DE:C970 Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:C970 Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2026 | €5.16 | €5.16 | 0.00% |
Mar 31, 2026 | €5.16 | €5.16 | 0.00% |
Nov 13, 2025 | €9.00 | €8.34 | -7.33% |
Aug 14, 2025 | €6.12 | €6.12 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Co-Diagnostics (DE:C970) report earnings?
Co-Diagnostics (DE:C970) is schdueled to report earning on Aug 06, 2026, Before Open (Confirmed).
What is Co-Diagnostics (DE:C970) earnings time?
Co-Diagnostics (DE:C970) earnings time is at Aug 06, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Co-Diagnostics stock?
The P/E ratio of Co-Diagnostics is N/A.
What is DE:C970 EPS forecast?
Currently, no data Available